AbbVie Inc (ABBV)vsDeciphera Pharmaceuticals LLC (DCPH)
ABBV
AbbVie Inc
$261.74
+1.79%
HEALTHCARE · Cap: $454.36B
DCPH
Deciphera Pharmaceuticals LLC
$25.59
0.00%
HEALTHCARE · Cap: $2.21B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 36711% more annual revenue ($64.39B vs $174.91M). ABBV leads profitability with a 9.8% profit margin vs -108.9%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
DCPH
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.4%
Fair Value
$151.82
Current Price
$261.74
$109.92 premium
Margin of Safety
+41.8%
Fair Value
$43.98
Current Price
$25.59
$18.39 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Revenue surging 34.5% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Weak financial health signals
ROE of -60.3% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : DCPH
The strongest argument for DCPH centers on Revenue Growth, Debt/Equity. Revenue growth of 34.5% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : DCPH
The primary concerns for DCPH are EPS Growth, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while DCPH is a hypergrowth play — different risk/reward profiles.
ABBV carries more volatility with a beta of 0.28 — expect wider price swings.
DCPH is growing revenue faster at 34.5% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 30/100) and 10.2% revenue growth. DCPH offers better value entry with a 41.8% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Deciphera Pharmaceuticals LLC
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to improve the lives of cancer patients by addressing key drug resistance mechanisms that limit the rate and durability of response to existing cancer therapies. The company is headquartered in Waltham, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?